Sarepta appoints Henri Termeer advisor to the company
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics, a developer of innovative RNA-targeted therapeutics, has named former CEO of Genzyme Henri Termeer a key advisor to the company. Mr Termeer is the former chair, president and CEO of Genzyme, where he served for nearly three decades before retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20bn.